Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
J Indian Med Assoc ; 2008 Dec; 106(12): 814-5
Article in English | IMSEAR | ID: sea-96333

ABSTRACT

The most common cause of gastroparesis is diabetes mellitus. The present study was carried out to asses the combination of itopride and pantoprazole in the treatment of diabetic gastroparesis. The study was an open label, multicentre, conducted in 743 patients with diabetic gastroparesis for a period of 3 weeks. The efficacy parameters included nausea, vomiting, early satiety, bloating, postprandial fullness, epigastric pain and regurgitation. The patients were evaluated based on the frequency and severity of symptoms and compared with the baseline scores. There were significant improvement in severity as well as the frequency of all the symptom parameters of the disease (p<0.001). The physicians' evaluation to the therapy was rated either excellent or good.


Subject(s)
2-Pyridinylmethylsulfinylbenzimidazoles/therapeutic use , Adolescent , Adult , Aged , Benzamides/therapeutic use , Benzyl Compounds/therapeutic use , Diabetes Complications/complications , Drug Therapy, Combination , Gastrointestinal Agents/therapeutic use , Gastroparesis/diagnosis , Humans , Middle Aged , Proton Pump Inhibitors/therapeutic use , Severity of Illness Index , Treatment Outcome , Young Adult
2.
J Indian Med Assoc ; 2008 Nov; 106(11): 752-4
Article in English | IMSEAR | ID: sea-100281

ABSTRACT

The aim of the study was to evaluate and document the efficacy and tolerability of rabeto plus (FDC of rabeprazole and itopride) in management of functional dyspepsia. It was an open, prospective, non-comparative, multidose study. The patients with functional dyspepsia (NERD or non-erosive reflux disease) attending OPD of a leading, tertiary care, teaching hospital in West Bengal (BS Medical College, Bankura) were inducted in the study. A total of 46 adult patients of either sex with functional dyspepsia and a clinical diagnosis of NERD were given 1 capsule of rabeto plus before breakfast, for up to 4 weeks. Primary efficacy variables were relief from symptoms of heartburn, nausea, vomiting, waterbrash and fullness. Secondary efficacy variables were global assessment of efficacy and toleration by patients and treating physicians. The tolerability was assessed on the basis of record of spontaneously reported adverse events with their nature, intensity and outcome. Out of 55 patients enrolled in the study, 46 completed the study as planned, while 9 patients were lost to follow-up (dropped). Most patients reported near total symptom relief by the end of study. Total symptom score showed remarkable and significant improvement from baseline to end of the study. Importantly, none of the patients reported any side-effect. All participants tolerated the drug well. Moreover, response to study drug was rated as excellent or good by over 93% patients and their treating physicians. This means that 9 out 10 patients receiving rabeto plus reported desired symptom relief from dyspepsia. Thus it was concluded that rabeto plus is a valuable drug for treatment of functional dyspepsia or NERD.


Subject(s)
2-Pyridinylmethylsulfinylbenzimidazoles/therapeutic use , Adolescent , Adult , Aged , Benzamides/therapeutic use , Benzyl Compounds/therapeutic use , Drug Therapy, Combination , Dyspepsia/complications , Female , Gastroesophageal Reflux/complications , Gastrointestinal Agents/therapeutic use , Humans , Male , Middle Aged , Prospective Studies , Proton Pump Inhibitors/therapeutic use , Treatment Outcome , Young Adult
3.
West Indian med. j ; 56(1): 17-21, Jan. 2007.
Article in English | LILACS | ID: lil-471843

ABSTRACT

The data compiled in the present review on dibenzyl trisulphide (DTS) isolated from Petiveria alliacea L (the guinea hen weed or anamu) revealed that the compound and its derivatives could be of tremendous pharmaceutical interest. The mode of action elucidated for DTS revealed that it is a mitogen activated protein extracellular regulated kinases 1 and 2 (MAPKinases erk1 and erk 2) signal transduction molecule. Dibenzyl trisulphide caused hyper-phosphorylation of growth factor induced MAPKinases (erk 1 and erk 2) phosphorylation, a process critical for the improvement of long term memory, and is implicated in neuronal growth. Dibenzyl trisulphide and its derivatives exhibited potent anti-proliferation/cytotoxic activity on a wide range of cancer cell lines. The cytotoxic activity of DTS was increased by 70-1000 fold when bound to albumin in vitro. Dibenzyl trisulphide seems to have a cytokine switching mechanism in which it down regulates cytokines from the Type I helper cells (Th -1 cell) pathway which contained several pro-inflammatory cytokines and up-regulates those on the Type 2 helper cells (Th-2) pathway. The trisulphide up-regulates some reticuloendothelial system parameters eg granulocyte counts and increased thymic and Peyer's patches masses via cell proliferation processes which are known to be regulated via the MAPKinase signal transduction pathway. When the zygotes ofAsternia pectinifera (Starfish) were exposed to DTS at concentration of 10 mM, a dose lethal to all cancer cells tested, it was observed that the sensitive process of protein biosynthesis was not affected Similarly, the proliferation of the HOFA human fibroblast, a noncancerous cell line, was not severely affected by DTS at 8.9 microM over seven days, a concentration also lethal to most cancer cell lines tested The implications of the findings will be highlighted in the present review.


Los datos compilados en el presente estudio sobre el trisulfuro de dibencilo (TSD) aislado a partir de Petiveria alliacea L (yerba de Guinea, ó anamú) revelaron que el compuesto y sus derivados podrían tener extraordinario interés farmacéutico. El modo de acción esclarecido en el TSD, reveló que se trata de una molécula de transducción de señales de proteínas kinasas 1 y 2 (MAP quinasas ERk 1 y 2) reguladas extracelularmente y activadas por mitógenos. El trisulfuro de dibencilo causó hiperfosforilación de la fosforilación de las quinasas MAP (Erk 1 y 2) inducidas mediante factor de crecimiento, un proceso crítico para el mejoramiento de la memoria a largo plazo, y que está implicado en el crecimiento neuronal. El trisulfuro de dibencilo y sus derivados mostraron una poderosa actividad citotóxica y antiproliferativa en una amplia gama de líneas celulares de cáncer. La actividad citotóxica del TSD se incrementaba de 70 á 1000 veces, cuando se vinculaba a la albúmin in vitro. El trisulfuro de dibencilo parece poseer un mecanismo conmutador citoquínico que regula por decremento las citoquinas provenientes de la vía de las células auxiliares de tipo 1 (células Th-1), que contiene varias citoquinas pro-inflamatorias y regula por incremento las de la vía de las células auxiliares de tipo 2 (Th-2). El trisulfuro regula por incremento los parámetros del sistema reticuloendotelial, p.ej. los conteos de granulocitos y el aumento tanto de las masas tímicas como de las masas de placas de Peyer, a través de los procesos de proliferación celular, de los cuales se sabe que son regulados mediante la vía de la transducción de señales de la quinasa MAP. Cuando los cigotos de Asternia pectinifera (estrella de mar) fueron expuestos al TSD a una concentración de 10 mM ­ una dosis letal para todas las células cancerosas sometidas a prueba ­ se observó que el proceso sensible de biosíntesis de la proteína no era afectado. De modo similar, la proliferación del fibroblasto humano HOFA ­ una línea celular no cancerosa ­ no fue afectada severamente por el TSD a 8.9 µM en siete días ­ una concentración letal para la mayoría de las líneas celulares cancerosas sometidas a prueba. Las implicaciones de los hallazgos se pondrán de relieve en el presente estudio


Subject(s)
Humans , Benzyl Compounds/therapeutic use , Plant Extracts , Phytotherapy , Sulfides/therapeutic use , Antigens, CD/physiology , Cadherins/physiology , Benzyl Compounds/pharmacology , Up-Regulation/physiology , Sulfides/pharmacology , Signal Transduction/drug effects
5.
Gac. méd. Méx ; 129(3): 201-5, mayo-jun. 1993. ilus
Article in Spanish | LILACS | ID: lil-177111

ABSTRACT

Se reporta un estudio clínico, doble ciego, controlado, para evaluar la eficacia y seguridad de ivermectina por vía bucal a la dosis de 200 mcg/kg de peso para el tratamiento de la escabiasis, efectuado en 55 pacientes. Los resultados informaron que 26 pacientes (79.3 por ciento) curaron con ivermectina en su primera visita de control, en comparación con cuatro (16 por ciento) del grupo que recibió placebó (X²= 77.07, p<0.001). Al final 37 pacientes de 50 (74 por ciento tratados con ivermectina curaron comparados con cuatro de 26 (16 por ciento) manejados con placebo. Esta diferencia es significativa (X²=23.66, p<0.001). Se concluyó que la ivermectina por vía oral efectiva y segura en el tratamiento de la escabiasis


Subject(s)
Humans , Male , Female , Adolescent , Antinematodal Agents/therapeutic use , Benzyl Compounds/therapeutic use , Skin Diseases, Parasitic/physiopathology , Mite Infestations/physiopathology , Ivermectin/administration & dosage , Onchocerciasis/therapy , Placebos/therapeutic use , Scabies/parasitology
SELECTION OF CITATIONS
SEARCH DETAIL